Elan, Biogen Tumble

Federated agrees to buy May; Qwest reportedly willing to revise offer for MCI; plus more of Monday's stocks in the news

Elan Corp. (ELN ) and Biogen Idec (BIIB ) announced the voluntary suspension in the marketing of Tysabri, a treatment for multiple sclerosis. The decision is based on recent reports of two serious adverse events; one fatal and one suspected case of PML.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.